Seeking fruitful Lenmeldy launch, Orchard names commercial chief to oversee world’s most expensive drug
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, promoting him to chief commercial officer after a year in which sales of the gene therapy fell short of expectations.
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, promoting him to chief commercial officer after a year in which sales of the gene therapy fell short of expectations.
